0000000000296627

AUTHOR

Giulio Cavalli

showing 8 related works from this author

IL-1 BLOCKADE IN PAEDIATRIC RECURRENT PERICARDITIS: A MULTICENTRIC RETROSPECTIVE STUDY OF THE ITALIAN COHORT

2019

Introduction: Acute pericarditis is an inflammatory condition causing the occurrence of pericardial effusion. In a third of patients, the disease is recurrent. First line treatment of idiopathic pericarditis consists in non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine; glucocorticoids represent the second line treatment in resistant or intolerant cases. A recent clinical trial has enlightened the effectiveness of anakinra in adults and paediatric patients with colchicine-resistant recurrent pericarditis. Objectives: To describe the clinical characteristics and response to treatment in a cohort of paediatric patients with recurrent pericarditis treated with IL inhibitors. Method…

Settore MED/38 - Pediatria Generale E SpecialisticaRecurrent pericarditis Anakinra Colchicine-resistence Canakinumab
researchProduct

Sociodemographic factors in fibromyalgia: results from the Italian Fibromyalgia Registry

2022

ObjectiveFibromyalgia (FM) is a chronic musculoskeletal pain syndrome of unknown aetiopathogenesis. Its development and maintenance are related to the interplay of biological, psychological, and contextual factors. Among the contextual factors, sociodemographic aspects are poorly elucidated. This study aimed to evaluate the relationships between sociodemographic/ clinical factors and symptom severity measures using a web-based registry of patients with FM.MethodsAdult patients with an ACR 2010/2011 diagnosis of FM underwent a clinical evaluation and were asked to complete questionnaires covering their sociodemographic data (gender, age, marital status, educational level), and disease-specif…

AdultMalesociodemographic factorsImmunologyReproducibility of ResultsSeverity of Illness IndexRheumatologysociodemographic factors.Surveys and QuestionnairesQuality of LifegenderImmunology and AllergyHumansFemalefibromyalgiaRegistriesChronic Painadult; female; humans; male; quality of life; registries; reproducibility of results; severity of illness index; sociodemographic factors; surveys and questionnaires; chronic pain; fibromyalgia
researchProduct

Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases.

2021

Abstract The interleukin (IL)-1 family member IL-1α is a ubiquitous and pivotal pro-inflammatory cytokine. The IL-1α precursor is constitutively present in nearly all cell types in health, but is released upon necrotic cell death as a bioactive mediator. IL-1α is also expressed by infiltrating myeloid cells within injured tissues. The cytokine binds the IL-1 receptor 1 (IL-1R1), as does IL-1β, and induces the same pro-inflammatory effects. Being a bioactive precursor released upon tissue damage and necrotic cell death, IL-1α is central to the pathogenesis of numerous conditions characterized by organ or tissue inflammation. These include conditions affecting the lung and respiratory tract, …

0301 basic medicineMyocarditisil-1βmedicine.medical_treatmentAutoimmunity Cancer Cytokines IL-1 IL-1αIL-1β Inflammation Interleukin 1 Receptor Antagonist Protein Receptors Interleukin-1 SARS-CoV-2 COVID-19 Interleukin-1alpha Humansil-1αImmunologyreceptorsInflammationmedicine.disease_causeAutoimmunityPathogenesis03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E Specialisticail-1Interleukin-1alphamedicinecancerImmunology and AllergyHumans030203 arthritis & rheumatologyAnakinrabusiness.industrySARS-CoV-2autoimmunityInterleukinCOVID-19Receptors Interleukin-1medicine.diseasecytokinesRilonaceptInterleukin 1 Receptor Antagonist Protein030104 developmental biologyCytokineinflammationImmunologyautoimmunity; cancer; cytokines; il-1; il-1α; il-1β; inflammation; humans; interleukin 1 receptor antagonist protein; receptors interleukin-1; SARS-COV-2; COVID-19; interleukin-1alphamedicine.symptombusinessinterleukin-1medicine.drugAutoimmunity reviews
researchProduct

The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients

2021

Abstract Objective Various studies have shown that overweight and obesity are central features of FM, but the real impact of a high BMI on clinical severity in patients with FM is still controversial. The aim of this study was to analyse the relationships between BMI categories and measures of symptom severity and functional impairment using data from a Web-based registry of patients with FM. Methods Adult patients with an ACR 2010/2011 diagnosis of FM underwent a complete physical examination and laboratory tests and were asked to complete a package of questionnaires covering their sociodemographic and treatment details, in addition to the following disease-specific questionnaires: the rev…

medicine.medical_specialtyobesityCross-sectional studyRevised Fibromyalgia Impact QuestionnaireOverweightNO03 medical and health sciencesBMI0302 clinical medicineRheumatologyInternal medicineFibromyalgiamedicineLS4_5030212 general & internal medicine030203 arthritis & rheumatologybusiness.industrymedicine.diseaseObesityDistressclinical severitywidespread painOriginal ArticlefibromyalgiaUnderweightmedicine.symptomAcademicSubjects/MED00010businessBody mass indexBMI; clinical severity; fibromyalgia; obesity; widespread pain
researchProduct

Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database

2021

ObjectiveThe role of age in influencing the severity of fibromyalgia (FM) is still controversial. The aim of this study is to define the contribution of age in the severity of FM from data from a large national database.MethodsThis cross-sectional study included adult patients with FM diagnosed according to the 2010/2011 American College of Rheumatology criteria. Disease severity was assessed with the revised Fibromyalgia Impact Questionnaire (FIQR) and the modified Fibromyalgia Assessment Status (FAS 2019mod). Patients were grouped into five age categories (between 18-40 years, between 41- 50 years, between 51-60 years, between 61-70 years, and =71 years). Differences in disease severity b…

AdultMaleSettore MED/16 - REUMATOLOGIAAdolescentImmunologyReproducibility of ResultsMiddle AgedFAS 2019mod.Severity of Illness IndexYoung AdultCross-Sectional StudiesRheumatologyagenational databaseSurveys and QuestionnairesQuality of LifeImmunology and AllergyHumansdisease severityFemalefibromyalgiaFIQR
researchProduct

Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients

2021

Abstract Objective To establish optimal cut-off values for the scores of the revised Fibromyalgia Impact Questionnaire (FIQR), the modified Fibromialgia Assessment Scale (FAS 2019mod), and the Polysymptomatic Distress Scale (PDS) in order to distinguish five levels of FM disease severity. Methods Consecutive FM patients were evaluated with the three clinimetric indices, and each patient was required to answer the anchor question: ‘In general, would you say your health is 1 = very good, 2 = good, 3 = fair, 4 = poor, or 5 = very poor?’—which represented the external criterion. Cut-off points were established through the interquartile reconciliation approach. Results The study sample consisted…

MalePercentileSettore MED/16 - REUMATOLOGIAFibromyalgiaCross-sectional studyseverityDiseaseSeverity of Illness IndexEconomica0302 clinical medicinemodifiedInterquartile rangeRetrospective StudieFibromyalgiaSurveys and QuestionnairesSurveys and QuestionnairePharmacology (medical)030212 general & internal medicinecut-off pointsPain MeasurementFibromyalgia Assessment Status; cut-off points; fibromyalgia; modified; polysymptomatic distress scale; revised Fibromyalgia Impact Questionnaire; severity; Cross-Sectional Studies; Female; Fibromyalgia; Follow-Up Studies; Humans; Incidence; Italy; Male; Middle Aged; Pain Measurement; Prognosis; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Quality of LifeIncidencerevised Fibromyalgia Impact Questionnairecut-off points; fibromyalgia; Fibromyalgia Assessment Status; modified; polysymptomatic distress scale; revised Fibromyalgia Impact Questionnaire; severityMiddle AgedPrognosisDistressItalyFemalefibromyalgiaFibromyalgia Assessment StatusHumanmedicine.medical_specialtyPrognosiRevised Fibromyalgia Impact QuestionnaireFollow-Up Studie03 medical and health sciencesRheumatologyInternal medicineSeverity of illnesscut-off pointmedicineHumansRetrospective Studies030203 arthritis & rheumatologyCross-Sectional Studiebusiness.industrymedicine.diseaseFibromyalgia Assessment StatuCross-Sectional StudiesFibromyalgia; severity; cut-off points; revised Fibromyalgia Impact Questionnaire; modified; Fibromyalgia Assessment Status; polysymptomatic distress scalepolysymptomatic distress scalefibromyalgia assessment status; cut-off points; fibromyalgia; modified; polysymptomatic distress scale; revised fibromyalgia impact questionnaire; severityQuality of LifebusinessFollow-Up Studies
researchProduct

Pediatric Recurrent Pericarditis: Appropriateness of the Standard of Care and Response to IL-1 Blockade

2022

Objective: To analyze, in a cohort of pediatric patients with recurrent pericarditis undergoing anti-interleukin (IL)-1 treatment: the agent and dosing used as first-line treatment, the long-term efficacy of IL-1 blockers, the percentage of patients achieving a drug-free remission, and the presence of variables associated with drug-free remission. Study design: Data were collected from patients' charts. The annualized relapse rate (ARR) was used for evaluation of treatment efficacy, and bivariate logistic regression analysis was used for variables associated with drug-free remission. Results: Fifty-eight patients, treated between 2008 and 2018, were included in the study (mean follow-up. 2.…

anti-inflammatory agents nonsteroidal colchicine interleukin-1 pericarditis steroids therapytherapySettore MED/38 - Pediatria Generale E SpecialisticaSettore MED/09 - Medicina Internaanti-inflammatory agents non-steroidal; colchicine; interleukin-1; pericarditis; steroids; therapyanti-inflammatory agents nonsteroidalanti-inflammatory agents non-steroidalPediatrics Perinatology and Child Healthanti-inflammatory agents nonsteroidal; colchicine; interleukin-1; pericarditis; steroids; therapypericarditiscolchicineinterleukin-1steroidsThe Journal of Pediatrics
researchProduct

La inocencia de Giulio. Andreotti no fue absuelto

2016

Desde su espectáculo solista Kabum!... come un paio di impossibilità (2006), estrenado bajo la dirección artística de Paolo Rossi, la dramaturgia de Giulio Cavalli (Milán, 1977) se ha caracterizado por tener una fuerte orientación cívica. Dos de sus obras de ese mismo año, 2006, pueden dar cuenta de ello: (Re) Carlo (non) torna dalla battaglia di Poitiers, sobre los trágicos hechos ocurridos durante la reunión del G8 en Génova en 2001, y Linate 8 ottobre 2001: la strage, sobre el acccidente aéreo que costó la vida a 118 pesonas. Aunque posteriormente ha ampliado su teatro a otros temas, como en Bambini a dondolo (2007), un drama sobre el turismo sexual infantil, han sido sus intensos espect…

lcsh:Language and LiteratureEstudios regionales y localesUNESCO::CIENCIAS DE LAS ARTES Y LAS LETRASlcsh:NX1-820teatro de narración:CIENCIAS DE LAS ARTES Y LAS LETRAS [UNESCO]Humanidadeslcsh:Pl'innocenza di giuliogiulio andreottilcsh:Arts in generaldenuncia civilZibaldone: Estudios Italianos
researchProduct